Mereo BioPharma Group Plc develops therapeutics for oncology and rare diseases, focusing on setrusumab for osteogenesis imperfecta and alvelestat for alpha-1-antitrypsin deficiency. The company also has oncology candidates and partnered programs like Navicixizumab.
MREO filed a patent for "vegf/dll4 binding agents and uses thereof" on Tue, November 15, 2022. The patent was officially published on Thu, September 7, 2023.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
